Green Cross Influenza Vaccine 'GC Flu' Begins Domestic Supply

GC Green Cross announced on the 27th that it has started domestic shipments of its quadrivalent influenza vaccine, 'GC Flu Quadrivalent Prefilled Syringe,' to be used in this year's National Immunization Program (NIP). GC Green Cross plans to supply 1.74 million doses of the influenza vaccine to the NIP at a unit price of 10,700 KRW. In addition, it was explained that Korea Vaccine's 'Kovax Flu Quadrivalent PF Injection,' produced using GC Green Cross's bulk material, also obtained national shipment approval the day before.

GC Green Cross's quadrivalent influenza vaccine 'GCC Flu Quadrivalent Prefilled Syringe' [Photo by GC Green Cross]

GC Green Cross's influenza vaccine is produced based on globally verified embryonated egg-based vaccine manufacturing technology. With over 80 years of accumulated data, it is said to have high safety. The company also stated that it produces influenza vaccines year-round to meet both domestic and export demands, enabling rapid vaccine supply.

A GC Green Cross official said, "Recently, there has been an unusual surge in influenza patients during the summer," adding, "We are glad to contribute to proactive responses against influenza outbreaks through faster shipments."

This content was produced with the assistance of AI translation services.